Summary
Signal counts
Assets tracked: 2
Watchlist assets: 1
Registry stop assets: 1
Sponsor overview
Ohio State University Comprehensive Cancer Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00983944 | https://clinicaltrials.gov/study/NCT03513562
Assets
Linked programs
- bleomycin sulfate: Registry Stop Signal (4/5)
- Ibrutinib: Low Signal (1/5)